Company profile

TILT Biotherapeutics Ltd.

Privately held: no public share price (University of Helsinki spin-out; €22.6M Series B closed May 2025, no public listing. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.globenewswire.com/news-release/2025/05/13/3079780/0/en/TILT-Biotherapeutics-Announces-Closing-of-USD-25-Million-Series-B-Financing.html]) · Finland

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
TILT-123
Phase 1
Tumor cells (oncolytic replication via Ad3 receptor); expressesOther
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.